子分类：
| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 121 | VERFAHREN ZUM NACHWEIS DES VORKOMMENS VON NIERENSTEINEN UND/ODER ENTZÜNDUNGEN DER ABLEITENDEN HARNWEGE | EP09741736.4 | 2009-04-28 | EP2277051A1 | 2011-01-26 | HOFFMANN, Werner |
| The invention relates to methods for detecting diseases of the excretory urinary tracts. The aim of the invention is to provide a method for detecting the existence of diseases of the excretory urinary tracts, which can be carried out non-invasively, thus allowing first indications of disease, e.g. in relation to the existence of renal calculi and/or inflammation (e.g. after urinary tract infections) of the excretory urinary tracts, to be rapidly and cost-effectively detected, in order to resolve e.g. microhaematuria caused by inflammation rapidly and cost-effectively. To achieve this, the presence or concentration of TFF-peptides is determined in the urine. | ||||||
| 122 | BACTERIAL VAGINOSIS APPARATUS AND DIAGNOSTIC METHODS | EP08799385.3 | 2008-09-10 | EP2188632A1 | 2010-05-26 | TYNAN, Katherine; SCHOOLNIK, Gary |
| The present disclosure relates to the filed of medical diagnostics, specifically directed towards the field of bacterial vaginosis diagnostic methods, systems and apparatus. Also included is a multiplexed platform test for the diagnosis of infectious vaginitis. | ||||||
| 123 | POLYPEPTIDMARKER ZUR DIAGNOSTIK UND BEURTEILUNG DER URETERABGANGSSTENOSE | EP06819862.1 | 2006-11-30 | EP1955064A1 | 2008-08-13 | MISCHAK, Harald; WITTKE, Stefan |
| The invention relates to a method for the diagnosis of ureteropelvic junction (UAS). In said method, the presence or absence of at least one polypeptide marker in a sample is determined, said polypeptide marker being selected from markers 1-277 (frequency markers), or the amplitude of at least one polypeptide marker is determined, selected from the markers 278-308 (amplitude markers), which are characterised by values for the molecular masses and the migration time (CE-time). | ||||||
| 124 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF GENITOURINARY DISORDERS, INCLUDING PRE-TERM LABOR AND LEIOMYOMAS | EP04783287 | 2004-09-07 | EP1667630A4 | 2008-07-23 | AL-HENDY AYMAN |
| 125 | METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF GENITOURINARY DISORDERS, INCLUDING PRE-TERM LABOR AND LEIOMYOMAS | EP04783287.8 | 2004-09-07 | EP1667630A2 | 2006-06-14 | AL-HENDY, Ayman |
| The present invention relates to an association between specific polymorphisms of the COMT polypeptide and the development, or risk of developing, preterm labor and uterine diseases and conditions. Disclosed are therapeutic, preventative and diagnostic methods and compositions relating to pre-term labor, uterine diseases and conditions, and ovarian conditions and diseases. In certain embodiments, such methods and compositions involve a COMT inhibitor. | ||||||
| 126 | METHODS OF USING PIGMENT EPITHELIUM DERIVED FACTOR (PEDF) FOR THE TREATMENT AND PREVENTION OF AGENT-INDUCED GONADAL OR UTERINE TOXICITY | EP15774029 | 2015-03-30 | EP3125924A4 | 2018-04-25 | SHALGI RUTH; CHUDERLAND DANA; BAR-JOSEPH HADAS; GOLDBERG KEREN; BEN-AHARON IRIT; STEMMER SALOMON M |
| A method of treating or preventing gonadal or uterine toxicity induced by an agent in a subject is provided. Accordingly there is provided a method comprising administering to a subject a therapeutically effective amount of pigment epithelium-derived factor (PEDF), thereby treating or preventing the gonadal toxicity induced by the agent. Also provided is, a method comprising determining gonadal function in a subject; and administering to the subject a therapeutically effective amount of PEDF, thereby treating or preventing the gonadal toxicity induced by the agent. Also provided is a PEDF for use in the treatment or prevention of gonadal toxicity induced by an agent in a subject. Also provided are cell culture, a medium, a kit and method for improving oocyte quality ex-vivo. | ||||||
| 127 | TREATING AND PREVENTING DISEASE WITH TMA AND TMAO LOWERING AGENTS | EP15843415 | 2015-09-25 | EP3197442A4 | 2018-04-04 | HAZEN STANLEY L |
| Provided herein are compositions, systems, and methods for treating a disease, such as kidney and/or cardiovascular disease, with an agent that reduces the production of trimethylamine (TMA) or trimethylamine-n-oxide (TMAO) in a subject. In certain embodiments, the agent is: i) 3,3-dimethyl-1-butanol (DMB) or a DMB derivative or related compound, ii) acetylsalicylic acid or derivative thereof (e.g., with an enteric coating for delivery to the colon and/or cecum); iii) a flavin monooxygenase 3 (FMO3) inhibitor; iv) a gut TMA lyase inhibitor; v) an antibiotic or antimicrobial; vi) a probiotic or prebiotic; vii) an antiplatelet agent; or viii) a TMA and/or TMAO sequestering agent. | ||||||
| 128 | METHODS AND SYSTEMS FOR THE DIAGNOSIS AND TREATMENT OF ANDROGEN DISORDERS | EP14761102 | 2014-03-04 | EP2965085A4 | 2016-10-26 | JASUJA RAVI; BHASIN SHALENDER; ZAKHAROV MIKHAIL N |
| 129 | METHOD FOR DETECTION OF, OR THE RISK OF, BLADDER CANCER | EP10737623.8 | 2010-07-29 | EP2460012B1 | 2016-04-20 | RUDDOCK, Mark, W.; REID, Cherith, N.; WILLIAMSON, Kathleen; LAMONT, John, V.; FITZGERALD, Stephen, P |
| 130 | Condensed pyridine derivate and use thereof | EP14167191.7 | 2008-11-14 | EP2789338A2 | 2014-10-15 | Matsumoto, Takahiro; Nagamiya, Hiroyuki; Maezaki, Hironobu; Kusumoto, Tomokazu; Yoshikawa, Kyoko; Furukawa, Hideki; Kamo, Izumi |
Described is a method of screening for a drug for the prophylaxis or treatment of cystoceles or enteroceles, comprising increasing an intravesical pressure after bilateral transection of the hypogastric nerve and pudendal nerve of an animal, and measuring a closure response in the urethra, the rectum or the vagina observed at that time.
|
||||||
| 131 | METHODS AND DEVICES FOR DETECTING DIABETIC NEPHROPATHY AND ASSOCIATED DISORDERS | EP10807277 | 2010-08-06 | EP2462437A4 | 2013-01-30 | SPAIN MICHAEL D; MAPES JAMES P; LABRIE SAMUEL T; MCDADE RALPH L; EISINGER DOMINIC; BALLARD KARRI L |
| Methods and devices for diagnosing, monitoring, or determining kidney transplant rejection or an associated disorder in a mammal are described. In particular, methods and devices for diagnosing, monitoring, or determining kidney transplant rejection or an associated disorder using measured concentrations of a combination of three or more analytes in a test sample taken from the mammal are described. | ||||||
| 132 | METHODS AND DEVICES FOR DETECTING KIDNEY TRANSPLANT REJECTION | EP10807278 | 2010-08-06 | EP2462438A4 | 2013-01-23 | SPAIN MICHAEL; MAPES JAMES P; LABRIE SAMUEL; MCDADE RALPH; EISINGER DOMINIC; BALLARD KARRI; SALOMON DANIEL; ABECASSIS MICHAEL |
| Methods and devices for diagnosing, monitoring, or determining kidney transplant rejection or an associated disorder in a mammal are described. In particular, methods and devices for diagnosing, monitoring, or determining kidney transplant rejection or an associated disorder using measured concentrations of a combination of three or more analytes in a test sample taken from the mammal are described. | ||||||
| 133 | DETERMINATION OF THE INTEGRITY OF RNA | EP09810713.9 | 2009-08-31 | EP2318508A1 | 2011-05-11 | DENISOV, Vladimir |
| Methods, systems, and apparatus make a determination of a level of integrity of a sample of biomolecules. For example, the determination of the integrity of RNA in a sample may be done in a fast and reproducible manner, such that the user can be assured of accuracy of a test (e.g. quantitative polymerase chain reaction qPCR) on the sample and compare results of different samples. The determination of integrity of an RNA sample is performed by comparing a size profile to reference size profiles (degradation standards) obtained from degradation over different lengths of times. As the reference scale of the level of integrity is derived from the actual degradation that occurs in a sample, high accuracy, reproducibility, and efficiency is provided. | ||||||
| 134 | BACTERIAL VAGINOSIS APPARATUS AND DIAGNOSTIC METHODS | EP08799385 | 2008-09-10 | EP2188632A4 | 2010-11-10 | TYNAN KATHERINE; SCHOOLNIK GARY |
| 135 | TREATMENT AND DIAGNOSIS OF OBLIGATE INTRACELLULAR PATHOGENS | EP06794763.0 | 2006-10-13 | EP1934598A2 | 2008-06-25 | AKHATOVNA ZIGANGIROVA, Nailya |
| This invention relates to the detection of pathogens, in particular persistent forms of obligate intracellular or membrane associated microorganisms such as Chlamydia, Mycoplasma and Ureaplasma species, in blood samples, in particular in plasma and serum samples. Methods and kits of the invention may be useful in detecting pathogen infections and assessing pathogen-associated disease conditions and also for development and screening of new anti-microbial drugs, products and therapies. | ||||||
| 136 | A NOVEL ANTIPROLIFERATIVE FACTOR AND METHODS OF USE | EP04777402 | 2004-07-01 | EP1648492A4 | 2008-04-09 | KEAY SUSAN K; SZEKELY ZOLTAN; MICHEJDA CHRISTOPHER |
| 137 | ANTIBODIES SPECIFIC FOR BLADDER NUCLEAR MATRIX PROTEINS BLCA-1 TO BLCA-6 | EP99944000.1 | 1999-08-30 | EP1107992A2 | 2001-06-20 | GETZENBERG, Robert, H. |
| Antibodies which specifically bind to nuclear matrix proteins (NMP) BLCA-1 to BLCA-6 which are characterized by a defined expression in tissue are provided. These NMPs are useful markers in diagnosing and monitoring the stage of malignancy of a cell and treating cell proliferative disorders associated with the NMP. | ||||||
| 138 | METHOD OF TREATING BLADDER AND LOWER URINARY TRACT SYNDROMES | EP99921690.6 | 1999-05-06 | EP1075486A1 | 2001-02-14 | SCHWINN, Debra, A. |
| The present invention relates to bladder and lower urinary tract syndromes, particularly, irrative symptoms, and to a method of treating same using α1d-adrenergic receptor (α1dAR) antagonists. The invention further relates to a method of screening compounds for their ability to serve as α1dAR selective antagonists. | ||||||
| 139 | ELISA FOR INTERSTITIAL CYSTITIS AND BLADDER CANCER | EP98955121.3 | 1998-10-26 | EP1027606A1 | 2000-08-16 | HAAK-FRENDSCHO, Mary; OKRAGLY, Angela, J.; NILES, Andrew, L.; SABAN, Ricardo |
| Disclosed is a method of diagnosing or monitoring interstitial cystitis or bladder cancer in a mammal. The method comprises analyzing urine of the mammal for the concentration of a urine-soluble protein selected from the group consisting of neurotrophin-3, nerve growth factor, glial cell line-derived neurotrophic factor, tryptase, and combinations thereof. | ||||||
| 140 | BLADDER NUCLEAR MATRIX PROTEINS AND THEIR USE IN DETECTING AND TREATING CELL PROLIFERATIVE DISORDERS | EP96936963 | 1996-11-01 | EP0810874A4 | 1998-12-16 | GETZENBERG ROBERT H; BAHNSON ROBERT R |
QQ群二维码
意见反馈
意见反馈